VICL - Vical Incorporated

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.80
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.80
Open1.80
Bid1.78 x 4800
Ask2.29 x 100
Day's Range1.78 - 1.83
52 Week Range1.66 - 3.70
Volume154,568
Avg. Volume415,143
Market Cap33.479M
Beta0.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Want To Invest In Vical Incorporated (VICL)? Here’s How It Performed Lately
    Simply Wall St.6 days ago

    Want To Invest In Vical Incorporated (VICL)? Here’s How It Performed Lately

    When Vical Incorporated (NASDAQ:VICL) announced its most recent earnings (30 September 2017), I did two things: looked at its past earnings track record, then look at what is happening inRead More...

  • Are Options Traders Betting on a Big Move in Vical (VICL) Stock?
    Zacks16 days ago

    Are Options Traders Betting on a Big Move in Vical (VICL) Stock?

    Investors in Vical (VICL) need to pay close attention to the stock based on moves in the options market lately.

  • Capital Cube19 days ago

    ETFs with exposure to Vical, Inc. : November 21, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cubelast month

    ETFs with exposure to Vical, Inc. : November 6, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017
    Capital Cube2 months ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q3, 2017 By the Numbers : October 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Vical, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 3.24 million, Net Earnings of USD -3.09 million. Gross margins narrowed from 62.41% to 45.12% compared to the same period last year, operating (EBITDA) margins now -92.13% from -86.71%. Change in operating cash ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VICL earnings conference call or presentation 23-Oct-17 4:00pm GMT

    Q3 2017 Vical Inc Earnings Call

  • Associated Press2 months ago

    Vical reports 3Q loss

    The San Diego-based company said it had a loss of 27 cents per share. The drug developer posted revenue of $3.2 million in the period. The company's shares closed at $2.38. A year ago, they were trading ...

  • Capital Cube2 months ago

    ETFs with exposure to Vical, Inc. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Vical, Inc. : September 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
    Capital Cube3 months ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Vical, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Vical, Inc. – CytRx Corporation, Newlink Genetics Corporation, Agenus Inc., Chimerix, Inc., Celldex Therapeutics, Inc., Sanofi Sponsored ADR, Pfizer Inc., Merck & Co., Inc. and Bristol-Myers Squibb Company (CYTR-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VICL earnings conference call or presentation 8-Aug-17 4:00pm GMT

    Q2 2017 Vical Inc Earnings Call

  • Associated Press4 months ago

    Vical reports 2Q loss

    The San Diego-based company said it had a loss of 30 cents per share. The drug developer posted revenue of $3.4 million in the period. The company's shares closed at $2.59. A year ago, they were trading ...

  • Capital Cube5 months ago

    ETFs with exposure to Vical, Inc. : June 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Vical, Inc. : June 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017
    Capital Cube6 months ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q1, 2017 By the Numbers : June 13, 2017

    Categories: Yahoo FinanceGet free summary analysis Vical, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Vical, Inc. – CytRx Corporation, Newlink Genetics Corporation, Chimerix, Inc., Agenus Inc., Celldex Therapeutics, Inc., Pfizer Inc., Merck & Co., Inc. and Bristol-Myers Squibb Company (CYTR-US, NLNK-US, CMRX-US, AGEN-US, ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of VICL earnings conference call or presentation 15-May-17 4:00pm GMT

    Q1 2017 Vical Inc Earnings Call

  • Associated Press7 months ago

    Vical reports 1Q loss

    The San Diego-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $3.2 million in the period. The company's shares closed at $2.26. A year ago, they were trading ...

  • Capital Cube8 months ago

    ETFs with exposure to Vical, Inc. : April 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Vical, Inc. :VICL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017
    Capital Cube9 months ago

    Vical, Inc. :VICL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 15, 2017

    Categories: Yahoo Finance Get free summary analysis Vical, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Vical, Inc. – Chimerix, Inc., Agenus Inc., Newlink Genetics Corporation, Celldex Therapeutics, Inc., Sanofi Sponsored ADR, Pfizer Inc., Merck & Co., Inc. and Bristol-Myers Squibb Company (CMRX-US, AGEN-US, NLNK-US, ... Read more (Read more...)

  • Associated Press9 months ago

    Vical reports 4Q loss

    The San Diego-based company said it had a loss of 25 cents per share. The drug developer posted revenue of $3.2 million in the period. For the year, the company reported that its loss narrowed to $9 million, ...

  • Capital Cube11 months ago

    ETFs with exposure to Vical, Inc. : January 6, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cubelast year

    ETFs with exposure to Vical, Inc. : December 13, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Vical, Inc. Here are 5 ETFs with the largest exposure to VICL-US. Comparing the performance and risk of Vical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)